Previous 10 | Next 10 |
2024-02-15 10:04:10 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investing in small-cap stocks offers multiple advantages for those looking to diversify their portfolios with potential high-growth opportunities efficiently. Small-cap stocks strike a unique b...
VANCOUVER, British Columbia, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that manage...
InMed Pharmaceuticals (NASDAQ: INM) , a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, has announced the appointment of Netta Jagpal, CPA, CA, as the newest member of its executive team; Jagpal will serve as the company chi...
VANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appoint...
2024-02-06 10:04:54 ET Summary Zymeworks' share price is moving higher lately, led by an overall recovery of biotech stocks, and possibly by increased investor interest in the company’s emerging antibody-drug conjugate platform. The topline results from the phase 3 trial of...
2024-02-03 09:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-31 13:04:00 ET Summary ZYME's partners, JAZZ and BGNE, are potentially within a year of approval and launch of zanidatamab, a bispecific anti-HER2 antibody. The approval and launch of zanidatamab in multiple markets could generate significant milestones and royalty streams...
2024-01-29 15:17:00 ET Summary Jazz Pharmaceuticals is likely to fall short of its 2025 revenue goal of $5 billion unless it makes a bold M&A move. Despite this, the stock looks undervalued and has the potential to re-rate higher, driven by the growth of Xywav, Rylaze, and Epi...
2024-01-08 02:11:54 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Unlocking the potential of small-cap stocks often reveals sky-bound potential. The three listed stocks in the article offer substantial growth opportunities. These three small-cap marvels are m...
2024-01-04 06:51:53 ET More on Zymeworks Zymeworks: Late-Stage Study Data In 2024 Makes This A Must-Watch Zymeworks lays out 2024 and 2025 outlook Zymeworks to raise ~$50M For further details see: Zymeworks names Jeffrey Smith as Chief Medical Officer
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that manage...
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...
Pursuant to the terms of the licensing agreement between Zymeworks and BeiGene, Zymeworks is entitled to receive an $8 million milestone payment from BeiGene and remains eligible to receive up to $164 million based on additional milestones plus royalties on product sales A Biologics License A...